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Cancer is one of the most common diseases afflicting people globally. New therapeutic
approaches are needed due to the complexity of cancer as a disease. Many current
treatments are very toxic and have modest efficacy at best. Increased understanding of
tumor biology and immunology has allowed the development of specific immunotherapies
with minimal toxicity. It is important to highlight the performance of monoclonal
antibodies, immune adjuvants, vaccines and cell-based treatments. Although these
approaches have shown varying degrees of clinical efficacy, they illustrate the potential
to develop new strategies. Targeted immunotherapy is being explored to overcome the
heterogeneity of malignant cells and the immune suppression induced by both the
tumor and its microenvironment. Nanodelivery strategies seek to minimize systemic
exposure to target therapy to malignant tissue and cells. Intracellular penetration has
been examined through the use of functionalized particulates. These nano-particulate
associated medicines are being developed for use in imaging, diagnostics and cancer
targeting. Although nano-particulates are inherently complex medicines, the ability to
confer, at least in principle, different types of functionality allows for the plausible
consideration these nanodelivery strategies can be exploited for use as combination
medicines. The development of targeted nanodelivery systems in which therapeutic and
imaging agents are merged into a single platform is an attractive strategy. Currently,
several nanoplatform-based formulations, such as polymeric nanoparticles, micelles,
liposomes and dendrimers are in preclinical and clinical stages of development. Herein,
nanodelivery strategies presently investigated for cancer immunotherapy, cancer targeting
mechanisms and nanocarrier functionalization methods will be described. We also
intend to discuss the emerging nano-based approaches suitable to be used as imaging
techniques and as cancer treatment options.
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INTRODUCTION
Cancer is a heterogeneous disease that results from a multi-step
process, characterized by uncontrolled tumor cell proliferation,
invasion and metastasis. Tumor cells have also the ability to evade
cell death (Fernald and Kurokawa, 2013) and to escape immune
system surveillance (Zitvogel et al., 2006).
Despite improvements in diagnosis and therapies, cancer is
still the most fatal disease worldwide with 11.5 million deaths
being predicted in 2030. Strategies for cancer treatment include
chemotherapy, radiotherapy, immunotherapy and surgery (Wu
et al., 2014). Many of these approaches are unspecific with
severe side effects (Peer et al., 2007). More effective and spe-
cific alternative treatments continue to be needed. In fact, it has
been described that those single treatment regimens have lim-
ited chances to eliminate cancer cells in a permanent manner
due to its heterogeneous nature (Hanahan and Weinberg, 2000;
Helmy et al., 2013).The success of cancer therapy is dependent
on the development of additional strategies to overcome severe
side effects, drug resistance and circumvent tumor evasion mech-
anisms (Girardi et al., 2001; Dunn et al., 2002; Koebel et al., 2007;
Chen et al., 2014b; Xu et al., 2014).
Although the general body immune response is often not
robust enough to escape to cancer cell tactics (Palucka and
Banchereau, 2012), our understanding of tumor immunology has
been evolving. It is accepted that tumor cells, parts of tumor
cells or even specific substances isolated from tumor cells can
be recognized by the immune system, which can then respond
to these malignant cells. The possibility for immune system-
based responses has brought new insights into the development
of novel cancer immunotherapy treatments. Immunotherapy has
begun to meet its promise for cancer treatment. Monoclonal anti-
bodies (mAbs) to specific targets that are engaged with tumor
mechanisms are used clinically, including alemtuzumab (lympho-
cytic leukemia) and trastuzumab (breast cancer) (Kirkwood et al.,
2012). Additionally, cancer vaccination has shown encouraging
preclinical results and has also been extensively explored, being
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mostly directed to the destruction of tumors by strengthening
the immune system (Rosenberg, 2001; Palucka and Banchereau,
2012).
The recognition of the crucial role of T-lymphocytes in can-
cer for immune-mediated treatments has contributed to the
exhaustive characterization of tumor-associated antigens (TAAs).
Of particular interest are the cytotoxic T Lymphocytes (CTL),
which upon antigen recognition can selectively target and destroy
malignant cells presenting epitopes which have been recognized.
However, their isolated response is often not enough and the
development of an optimal cancer vaccine seems to be depen-
dent on an effective stimulation and cooperation between CTL
and T helper (Th) cells specific for a tumor epitope (Fong
and Engleman, 2000; Banchereau et al., 2001; Palucka and
Banchereau, 2012).
In addition to the evolution of tumor immunology, there has
been progress in the development of nanodelivery systems. These
systems have the potential to overcome some of the drawbacks
of current chemotherapy and radiotherapy therapies. As reviewed
by Chow andHo (2013), nanosystems can display improved phar-
macokinetics and targeting of tissues and cells to enhance efficacy,
specificity and lower toxicity. Accordingly, nanosystems designed
to target immune molecules and cells may allow the development
of approaches that will use the patient’s immune system as a more
specific tool to fight cancer.
Nano-based platforms have also been explored for immune
cell labeling, using fluorescence and molecular imaging tech-
niques. As a result, immune cell mechanisms engaged in cancer
development and tumor metastasis can thus be better under-
stood, guiding the development of advanced platforms able to
specifically target and track immune cells.
CANCER AND THE IMMUNE SYSTEM
INNATE AND ADAPTIVE IMMUNITY TO CANCER
The immune system is composed of two main branches—innate
and adaptive immune responses. The innate immunity is a
non-specific first line defense of our body against antigens. It
comprises anatomic, physiologic, phagocytic, and inflammatory
barriers, such as skin or macrophages and neutrophils. On the
other hand, adaptive immunity is a highly specific component of
the immune system, which is stimulated by a specific antigen chal-
lenge to the organism. Still, the latter is not independent from the
innate response, since antigen-presenting cells (APCs), involved
in innate immunity, play a pivotal role in specific immunity
activation (Roitt and Delves, 2001; Kindt et al., 2006).
Dendritic cells (DCs), along with macrophages and B lympho-
cytes, are described as APCs (Roitt and Delves, 2001; Gogolak
et al., 2003; Kindt et al., 2006). DCs are the most powerful
“professional” APCs, being present in the majority of mam-
malian tissues and acting as an interface between innate and
adaptive immunity. They control and regulate the immune sys-
tem. DCs are organized in an intricate network throughout the
human lymphatic and non-lymphatic tissues, having different
functions, depending on their stage of maturation (Banchereau
et al., 2003; Bodey et al., 2004; Palucka and Banchereau, 2012).
Non-activated immature DCs capture antigens and induce tol-
erance in the steady state, whereas mature antigen-loaded DCs
can prime an antigen-specific immune response. DCs can also
be categorized in three main subsets—(i) Langerhans cells (LCs);
(ii) interstitial DCs (intDCs) and (iii) plasmocytoid DCs (pDCs).
Though all subsets derive from the same precursor cells—CD34+
hematopoietic stem cells, found in the marrow—they are origi-
nated from twomajor distinct pathways (Banchereau et al., 2003).
LCs and intDCs arise from the myeloid pathway, are CD11c+ and
both produce IL-2. LCs are present in stratified epithelia, like skin
and upper airways, whilst intDCs may be found in all other tis-
sues. Additionally, intDCs can secrete IL-10 and elicit naïve B cell
differentiation (Gogolak et al., 2003). The other parallel pathway
originates phenotypically CD11c− pDCs with the ability to pro-
duce high amounts of type I interferon and to modulate T cell
differentiation (Gogolak et al., 2003).
In tumor immunology, DCs are crucial for the presentation
of TAAs and to stimulate the immune system after DC activation
(Palucka and Banchereau, 2012). DCs patrol the different tissues,
processing exogenous and endogenous antigens that are then pre-
sented to T lymphocytes, after DC maturation. The maturation
process of DCs can be induced directly through “danger signals”
detected by pattern recognition receptors (PRRs) or triggered by
the presence of inflammatory mediators, such as TNF-α or IL-1β
(Bodey et al., 2004).
Antigen presentation to T lymphocytes by DCs occurs through
T-cell receptors (TCRs) that recognize antigens bound to major
histocompatibility complex (MHC) molecules. MHC proteins
can be sorted in two main groups: MHC class I—expressed on
the membrane of the majority of nucleated cells in vertebrates—
and MHC class II, only found in APCs (Levine and Chain, 1991;
Bodey et al., 2004). After the contact of a naïve T cell with
MHC-antigen complex, T cells proliferate and differentiate in
both memory T cells and effector T cells. Effector T cells may be
divided in T helper (Th—CD4+) or T cytotoxic (Tc—CD8+)
cells (Guermonprez et al., 2002; Gogolak et al., 2003). The stim-
ulation of Tc cells can lead to the generation of CTLs that secrete
low levels of cytokines, unlike Tc cells. However, they display cell-
killing action, controlling and eliminating cells that exhibit any
type of antigen, such as infected cells or tumor cells (Gogolak
et al., 2003). Other innate lymphocytes subsets, such as γδ T cells,
natural killer (NK) and natural killer T (NKT) cells, have been
reported as being engaged in a complex immunomodulatory net-
work, displaying anti-tumor activity. Preclinical studies described
that NKT cells can exhibit anti-tumor or immune-regulatory
mechanisms (Gajewski et al., 2013).
The interaction among B cells, T cells and mature DCs results
in an integrated immune response. Therefore, DCmigration from
the tumor site of antigen capture to secondary lymphoid organs
can thus greatly broaden antigen-specific T cell responses, pro-
moting effective anti-tumor immune responses that will lead
to tumor rejection and regression (Palucka and Banchereau,
2012).
A promising nano-based strategy has been designed in order to
develop synthetic DCs for T cell activation and immunotherapy,
based on semi-flexible and filamentous polymers (Mandal et al.,
2013). Effective antitumor-immune responses are thus dependent
on the development of alternative systems to deliver antigens to
DCs and promote their presentation to T cells. These factors are
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important to bear in mind when developing an effective vaccine
(Gajewski et al., 2013).
CANCER IMMUNE REGULATION AND EVASION MECHANISMS
Cancer immunosurveillance
Paul Ehrlich proposed the concept of the immune system as a
useful strategy against cancer, in the beginning of the Twentieth
century (Ehrlich, 1909). Some decades after, Thomas and Burnet
postulated the immunosurveillance theory based on Ehrlich’s
hypothesis. Cancer arousal was suggested to be caused by the
lack of efficiency of the immune system or the modification in
antigen expression of tumor cells, leading to its evasion (Burnet,
1957; Thomas, 1982). Thomas and Burnet also claimed that anti-
tumor immune response generally happens at an early stage of the
cancer development (Burnet, 1957; Thomas, 1982). Therefore,
once the tumor has grown, it escaped the immunosurveillance
barrier and started developing additional mechanisms to evade
from the immune system (Ahmad et al., 2004). Nevertheless,
Strutman’s later studies showed that cancer susceptibility of
immune-competent mice was similar to that observed in mice
with major immunodeficiency, setting against the immuno-
surveillance hypothesis (Shankaran et al., 2001; Dunn et al.,
2002). In the beginning of this century, the immunosurveil-
lance hypothesis was revised, as several studies have shown that
the immune system may not only destroy tumor cells but also
shape their phenotypes, leading to reduction of immunogenicity
(Shankaran et al., 2001; Dunn et al., 2002; Schreiber et al., 2011).
Currently, there is increasing evidence that tumor cells can be
recognized and destroyed by the immune system, as developing
tumor cells often co-express tumor antigens and ligands for acti-
vating receptors (Schreiber et al., 2011). Therefore, it is important
to describe which immune components display major roles in
tumor rejection. It is also important to clarify the appropriate
time and efficient type of action (Swann and Smyth, 2007).
Cancer immunoediting and cancer-related inflammation
As reviewed by Schreiber et al. (2011), cancer immunoediting can
be divided in three different phases: “elimination,” “equilibrium”
and “escape.”
In the first stage—“elimination”—both innate and adaptive
immunities act combined to identify the formation of tumor cells
and to destroy them, resembling the immunosurveillance theory.
Although many mechanisms are still poorly known, it has been
reported that cytokines, “danger signals” and DCs have impor-
tant roles in this phase (Sims et al., 2010; Vesely et al., 2011).
It has also been suggested that the required components for an
effective “elimination” depend on specific characteristics of the
tumor cells, such as its origin or anatomical location (Sims et al.,
2010). If the “elimination” stage is well succeeded, tumor cells are
destroyed, constituting an endpoint for cancer immunoediting
(Schreiber et al., 2011; Vesely et al., 2011).
The next stage—“equilibrium”—is described as a period of
tumor latency. In other words, when a tumor cell survives the
elimination phase, the adaptive immune response can control
tumor cell growth and shape its immunogenicity. “Equilibrium”
is believed to be the longest phase of cancer immunoediting pro-
cess. It seems to allow cancer cells to reside in patients’ body even
decades before it restarts to grow and become clinically evident
(Schreiber et al., 2011; Vesely et al., 2011).
The third phase—“escape”—occurs when tumor cells have
developed the ability to evade the mechanisms of recognition
of the immune system and/or their elimination. Tumor cells
are thought to progress from “equilibrium” phase to “escape”
through several mechanisms and/or pathways. For instance, an
alteration in immune system response, which may be triggered by
cancer-induced immunosuppression or a change in tumor cells
induced by immunoediting, or even immune system deteriora-
tion (Schreiber et al., 2011; Vesely et al., 2011).
Cancer immune evasion mechanisms
Cellular immunity has been shown to play amajor role in the con-
trol of tumor generation. Even though, recent findings revealed
that tumors often manage to evade it through several different
mechanisms. It has been reported that there is a reduction or even
loss of MHCI molecules, mostly associated to gene mutations
or impairment of MHCI-dependent antigen processing (Garrido
and Algarra, 2001; Ahmad et al., 2004; Vesely et al., 2011). In addi-
tion, an antigenic drift in cancer cells has lately been observed and
appears to be related with the mutation, loss or down-expression
of TAAs in tumor cells (Uyttenhove et al., 1997; Ahmad et al.,
2004). Similarly, the lack or reduction of the expression of co-
stimulatory patterns by tumor cells direct T lymphocytes to an
anergy state. These mechanisms altogether seem to reduce and
difficult the detection of cancer cells by CTLs and NK cells, which
consequently leads to tumor growth (Ahmad et al., 2004).
Alterations in apoptotic receptor signaling seem to help tumor
cells to evade the immune system. Molecules such as phos-
phatidylinositol 3-kinase (PI3K), protein kinase B and Fas ligand
(FasL) have modified expression and might be implicated in this
process (Davidson et al., 1998; Osaki et al., 2004).
Tumor eradication is also dependent on the manipulation
of immunosuppressive properties of tumor microenvironment,
where inducing and suppressing cytokine imbalance impairs DC
activation and maturation, compromising immune cell effec-
tor properties and supporting tumor growth. Tumor cells can
indeed secrete immunosuppressive molecules, including vascu-
lar endothelial growth factor (VEGF), IL-10 and transforming
growth factor-β (TGF-β) (Fortis et al., 1996; Tsushima et al.,
1996; Oyama et al., 1998). VEGF appears to be responsible for
down-regulation of NF-κB expression, which interferes in DC
maturation and differentiation, limiting the immune response
against tumor cells (Oyama et al., 1998). On the other hand, TGF-
β1 is an immune suppressive cytokine involved in the conversion
of CD4+T cells into immunosuppressive T regulatory (Treg) cells
that are mainly produced by DCs and tumor cells (Zou, 2005).
These immunosuppressive molecules are interesting targets to
achieve tumor growth inhibition and might be a very useful tool
for cancer immunotherapy. The use of nanoparticles (NPs) con-
taining small interfering RNA (siRNA) to knock-down TGF-β in
the tumor microenvironment has resulted in increased levels of
CD8+ T cells and lower number of Treg cells, leading to tumor
growth inhibition by 52% (Xu et al., 2014). A similar strategy
using polyethylenimine-capped silica NPs carrying VEGF siRNA
has been designed as a highly effective approach for lung cancer
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growth suppression andmetastasis (Chen et al., 2014b). High lev-
els of indoleamine 2,3-dioxygenase have also been found in tumor
microenvironment, reducing tryptophan pool levels, which drive
T lymphocytes to be arrested at G1 phase of the cell cycle (Ahmad
et al., 2004).
TUMOR MICROENVIRONMENT: TUMOR-INFLITRATING IMMUNE CELLS
AND RELATED REGULATORY PATHWAYS
The progress of cancer disease results from several mechanisms
developed by tumors to evade antitumor immune responses
(Section Cancer immune evasion mechanisms), which has been
associated mostly to tumor microenvironment molecular path-
ways and infiltrating cells at this particular region, rather than the
ignorance and defects of anti-tumor T cells (Gajewski et al., 2013;
Ma et al., 2013). In fact, the presence of different cells and their
dynamic interaction with malignant cells have a profound effect
on tumor progression (Mishra et al., 2010; Bussolati et al., 2011;
Cortez-Retamozo et al., 2012; Rahir and Moser, 2012).
It is widely accepted that the density of T cell infiltrates within
tumor microenvironment is the most important factor to pre-
dict cancer patients’ survival (Eerola et al., 2000; Oble et al., 2009;
Mahmoud et al., 2011). Nevertheless, macrophages are also cur-
rently recognized as a fundamental cell type. As a heterogeneous
population, its dual function toward cancer is determined by their
polarization status (Mantovani and Sica, 2010). Macrophages
are regulated by transcription factors, which will lead to differ-
ent phenotypes of tumor-associated macrophages (TAMs). M1
and M2 have been already characterized, being associated to
the pathogenesis of several diseases, namely inflammatory and
tumor diseases (Sica et al., 2006). Indeed, pro-inflammatory M1
macrophages, after being activated by IFN-γ, favor Th1 immune
cell activity and potentiate the eradication of malignant cells. On
the other hand, M2 phenotype enables Th2 immune responses
and regulate tissue repair, presenting pro-tumoral abilities in sev-
eral tumor types (Sica and Mantovani, 2012; Cornelissen et al.,
2014). Moreover, the production of several cytokines, such as
IL-1, IL-6, IL-10, VEGF, and TGF-β by M2 TAMs elicits the pro-
liferation and metastasis of tumor cells (Biswas and Mantovani,
2010). As a result, it has been described that the number of M2
macrophages and the overall M2/M1 ratio of TAMs are impor-
tant predictors of survival for distinct types of cancers, namely
melanoma (Erdag et al., 2012; Herwig et al., 2013), ovarian can-
cer (Lan et al., 2013; Colvin, 2014), T-cell (Niino et al., 2010), and
B-cell lymphomas (Nam et al., 2014), breast (Leek et al., 1996)
and pancreatic cancer (Ino et al., 2013).
It is important to mention however that the M1 and M2 clas-
sification of TAMs is not static, being usually very complex and
seems to be dictated by several mediators resultant from cel-
lular cross-talk and environmental conditions (Cai et al., 2012;
Escribese et al., 2012; Shime et al., 2012). Even tough, the causes
underlying the differentiation of TAMs to M1 or M2 phenotypes
are not yet fully understood. Type I interferon pathway seems
to be fundamental for the activation of innate immune response
against tumor cells. However, the production of type I interferon
by DCs remain an underexplored issue (Fuertes et al., 2011).
DCs are also present within tumor microenvironment, where
they can recognize and capture live and dying tumor cells
(Dhodapkar et al., 2008; Ma et al., 2013). Their presence in
tumors of different stages and grades correlates to prolonged dis-
ease survival and lower invasiveness, as reviewed in Palucka and
Banchereau (2012). Even though, some of this heterogeneous
hematopoietic lineage displays anti-tumor effects while others
present immunosuppressive functions at tumor site. Actually,
tumor-infiltrating DCs functionality may vary according to the
combination of environmental factors and pathways within vari-
able tumor site. Among DC subsets, it should be emphasized the
role of tumor-infiltrating plasmacytoid DCs (pDCs) and CD8α+
DCs lineage, being the first often related to T cell tolerance, while
the latter is in fact particularly efficient in the cross-presentation
of antigens via MHCI pathways and thus in cytotoxic T-cell
immunity (Hildner et al., 2008; Fuertes et al., 2011; Watkins et al.,
2011).
The characterization of different solid tumors, as melanoma,
showed the presence of tumor-infiltrating lymphoid cell lineage,
including CD8+ T cells. Their function is mainly compromised
by immune system-inhibitory pathways at tumor microenviron-
ment, enabling T cell anergy (Gajewski et al., 2013). It has been
reported the presence of high amounts of CD4+ Foxp3+ regula-
tory T cells (Treg cells) that are attracted by the chemokine CCL22
via CCR4 (Toulza et al., 2010; Spranger et al., 2013). However,
the function of T-cell subsets within tumor microenvironment is
highly complex, depending on several factors, such as the type of
receptors primed.
Another hypothesis for the presence of T cells within the
tumor microenvironment of certain tumors may be related to the
formation of a lymph node-like structure called tertiary lymphoid
tissues, where it is possible to find B cells, T cells and activated
DCs (Messina et al., 2012). Still, it is not clear if the formation
of those lymphoid structures is involved in tumor growth in vivo.
On the other hand, tumor-infiltrated T cells can express CCL21.
CCL21 is related to tumor tolerance by stimulating naïve T cells
to which the presentation of TAAs will not be efficient due to the
absence of co-stimulatory factors (Shields et al., 2010).
NK, NKT and γδT cells also seem to have an important role in
the immunomodulation of tumormicroenvironment (Peng et al.,
2007; Mishra et al., 2010; Marcu-Malina et al., 2011; Liu et al.,
2012). The antitumor effect of NK has been linked to solid and
hematopoietic tumors, while γδT cells and NKT cells have been
involved in tumor inhibition. However, they show immunoregu-
latory functions in certain circumstances that are not completely
known (Peng et al., 2007; Mishra et al., 2010; Marcu-Malina et al.,
2011; Liu et al., 2012). A promising strategy has been focused in
the stimulation of DCs by α-galactosylceramide to prime NKT,
promoting the production of IFN-γ (Shimizu et al., 2013).
Besides these cells, tumor stroma has also been associated
with tumor growth and includes different elements as colla-
gen, endothelial cells, fibroblast and several macrophage subsets,
which contributes for tumor immune evasion. In addition, higher
levels of angiogenic factors were found in tumors where the pres-
ence of tumor-infiltrating T cells is poor (Danhier et al., 2010).
Themajor immunosuppressive mechanisms include the secretion
of IL-10, TGF-β, and CCL22 by M2 macrophages (Condeelis and
Pollard, 2006). The trafficking of T cells within tumor microenvi-
ronment has been related to the secretion of different chemokines
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by stromal cells, namely CXCL9 and CXCL10 (Gooden et al.,
2011).
Nevertheless, the inherent complexity of the immune regula-
tion within tumor microenvironment and the incomplete defi-
nition of those multiple mechanisms demand additional efforts
to characterize these processes. Such characterization would sup-
port the development of translational alternative immunother-
apies (Mellman et al., 2011). For example, the presence of
tumor-infiltrating T cells within tumor site may indicate that
this particular type of tumor is a potential candidate for an
immunotherapeutic strategy due to their ability to support the
migration of T cells toward this particular region. However,
the multiple factors involved in the immune system inhibition
indicate that the use of complementary targeted strategies to
improve the presence of anti-tumor T cells and the knock-down
of immune inhibitory pathways may lead to optimal therapeutic
approaches.
Combinatory approaches for cancer therapy need indeed
to consider the successful modulation of the tumor-associated
cytokine network and cell communication within tumor
microenvironment. This will prevent the inhibition of anti-tumor
responses and down-regulate the proliferation of malignant
cells. The characterization of these immunoregulatory processes
and the deeper understanding of the immunological features
within tumor microenvironment have fostered the recognition of
biomarkers. Such recognition has been driving the design of novel
targeted therapies to block those pathways, including targeted
nanomedicines to tumor microenvironment to better avoid off-
targeted effects. The anti-CTL4monoclonal antibody ipilumimab
approved in 2011 by the US Food and Drug Administration
(FDA) to treat patients with advanced melanoma, constitutes
the first successful approach that targets one of those inhibitory
pathways (Mellman et al., 2011).
The design of these tumor-targeted systems is also influenced
by a variety of specific features presented by this region, when
compared to healthy tissues. Among those different properties,
vasculature and pH have been the most explored toward the
development of alternative and specific therapeutic nanosystems
(Fernald and Kurokawa, 2013; Torchilin, 2011). Angiogenesis
guarantees the supply of oxygen and different nutrients to tumor
cells. It results from the action of different factors, as pro-
angiogenic proteins, extracellular matrix proteins and matrix
metalloproteinases. This process is fundamental for the progres-
sion of the disease and has guided the development of different
targeted nanocarriers due to the particular morphology of the
blood vessels, as reviewed by Torchilin (2011). In fact, abnormal
architecture of blood vessel caused by incomplete angiogenesis
allows the retention of different nanodelivery systems specifically
at this particular tumor region, due to the so-called “Enhanced
Permeability and Retention” (EPR), which will be described in
Section Passive Targeting.
CANCER IMMUNOTHERAPEUTIC INTERVENTIONS
Cancer immunotherapy has been explored for some decades.
This term is often used to describe treatments based on mod-
ulation of the immune system through “active” or “passive”
approaches. The concept of immunotherapy relies on specific
immunemechanisms and targets, which could confer greater effi-
cacy and specificity with less toxicity. Therefore, improving the
presence of anti-tumor T cells and the knock-down of immune
inhibitory pathways, leading to optimal therapeutic approaches.
ACTIVE CANCER IMMUNOTHERAPY
Active cancer immunotherapy or cancer vaccination consists in
direct stimulation of the patient’s immune system so it can
act against tumor cells. Unlike infectious disease vaccination,
which efficiency is based mainly on neutralizing antibodies
and B-lymphocyte response, cancer vaccination depends on the
induction of CTL responses and on the administration of TAAs
to stimulate a systemic immune response.
Cancer vaccines are expected to induce a tumor specific
immune response able to either eliminate the malignant cells or
keep it under constant restraint, delaying tumor recurrence and
prolonging survival. Both prophylactic and therapeutic vaccine-
based cancer therapies have been proposed to enhance a specific
immune response to tumor cells, concerning DC activity, as sum-
marized in Vacchelli et al. (2012). It has also been reported
the prominence of DCs on CTL induction, thus becoming a
striking target for cancer vaccination (Section Strategies for DC
Targeting).
The extensive research has led to engineered biotech
molecules, such as proteins, peptides, antibodies and oligonu-
cleotides, designed to enhance immune-basedmechanisms, being
promising players to re-shape the future of immunotherapeu-
tic outcomes. However, as these candidates move toward clinical
investigation, it becomes clear that their biological effect depends
on the development of a tool able to attain their transport across
biological barriers. Accordingly, the potential of these bioactive
molecules has pointed nanomedicines as an approach to ensure
the target selectivity and safety required for their therapeutic
in situ efficacy, enabling their clinical application.
As discussed by Silva et al. (2013), an ideal vaccination strat-
egy involves the administration of the most immunogenic TAAs
along with the most effective adjuvants, including delivery plat-
forms. This will prime the tumor- specific T cells, induce tumor-
specific antibodies and kill tumor cells by host immune effector
mechanisms.
Several TAAs have been identified and characterized permit-
ting their use in the design of targeted delivery systems (Bos
et al., 2012; Engels et al., 2013). TAAs can be sorted as shared
tumor antigens—when present in many types of tumors and with
a distinct or absent expression on normal tissues (i.e., MAGE,
GAGE and NY-ESO1)- or unique tumor antigens. These anti-
gens result from point mutations or splicing alterations and are
expressed only by a specific tumor (Higgins et al., 2009; Pejawar-
Gaddy et al., 2010). However, those newly identified antigens, as
recombinant proteins, are usually weakly immunogenic, requir-
ingmultiple administrations and their association with adjuvants.
It has been described that both antigen and adjuvant must act in
a concerted way on the same APC, which can be provided by a
singular delivery system (Schlosser et al., 2008; Krishnamachari
et al., 2011; Raaijmakers et al., 2013).
As previously mentioned, the focus of cancer vaccines is the
stimulation of a cell-mediated immunity, rather than humoral
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responses. As many TAAs are intracellular proteins, fragments of
these peptides must be presented on the cell surface bound to
MHC class I molecules to be recognized by the immune system
(Henderson et al., 2005). Indeed, after the recognition of TAA-
MHCI complexes, in lymph nodes (Manolova et al., 2008), CD8+
T lymphocytes can proliferate and differentiate into CTLs. CTLs
are then able to migrate to peripheral tissues to develop contact-
mediated cytotoxicity activity and secrete effector cytokines as
IFN-γ and TNF-α, leading to local inflammation (Ahlers and
Belyakov, 2010).
Pattern recognition receptors, mainly the toll-like receptor
(TLR) family, are suitable targets to potentiate the presenta-
tion of TAAs through MHCI pathway to CD8+ T cells and
increase cancer immunotherapy efficacy. Among TLR agonists,
both cytosine phosphorothioate-guanine motifs (CpG; TLR9-
ligand), double stranded RNA mimic polyinosinic:polycytidylic
acid (poly(I:C); TLR3-ligand) and monophosphoryl lipid A
(MPL) have been associated to stronger anti-tumor immune
responses (Banchereau et al., 2003; Hildner et al., 2008; Radford
and Caminschi, 2013).
Generally, TAAs and TLR ligands carried by polymeric parti-
cles have the ability to escape the degradation in endosomes and
reach the cytosol in higher concentrations than those adminis-
tered in soluble form. Those antigens can thus be presented by
MHC-I molecules more effectively and for longer periods of time,
leading to an effective cellular response, which is fundamental for
a successful eradication of cancer cells.
PASSIVE CANCER IMMUNOTHERAPY
Passive immunotherapy is based on the administration of ex vivo
generated immune effector molecules or cells, such as antibodies
and CTLs, respectively. These molecules or cells can target specific
receptors, leading to enhanced efficacy of the treatment and also
to fewer side effects.
Monoclonal antibodies (mAbs)
Monoclonal antibodies are the main cancer immunotherapy
used currently in clinic to treat solid tumors and lymphomas
(Krishnamachari et al., 2011). For example, trastuzumab has been
used to treat HER2+ breast cancer and adenocarcinoma, whilst
alemtuzumab has been applied in chronic lymphocytic leukemia
treatment (Lee et al., 2013).
The mechanism of action of mAbs is related to their abil-
ity to interfere with both growth factor ligands and receptors or
pro-apoptotic targets, inducing apoptosis of cancer cells. Besides,
mAbs may activate components of the immune system through
Fc-region-based mechanisms. This leads to antibody-dependent
cell-mediated cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC) responses by macrophages and NK cells
(Krishnamachari et al., 2011).
The use of mAbs in clinic has been increasing in the last
decades. The first generation of mAbs used in cancer therapy
was originated frommouse. Their origin often resulted in limited
half-life, decreasing mAbs efficacy. Further progresses conducted
to the development of chimeric mAbs, with enhanced proper-
ties, and then humanized mAbs. Nowadays, fully human mAbs
are already available (Lee et al., 2013). Several novel mAbs for
different cancer types are presently in clinical trials, as reviewed
by Lee et al. (2013). For example, ganitumab—for pancreatic
cancer –and necitumumab—for non-small cell lung cancer—are
now in phase III of clinical trials.
Adoptive T-cell therapy
This approach is based on the transfer of mature tumor-reactive
T lymphocytes to act against tumor cells. Unlike cancer vaccines,
this strategy is independent from an immune response elicited by
an exogenous antigen. Instead, it relies on the delivery of a great
amount of ex vivo-expanded cells (Gajewski, 2012; Kirkwood
et al., 2012; Helmy et al., 2013).
Adoptive T-cell therapy with tumor-infiltrating lymphocytes
(TILs) has been proposed. In a successful study, autologous
TILs—T cells with potent antitumor activity found within
tumors—were harvested, activated ex vivo and reinfused in
patients. The total remission was reported in more than 20% of
the treated patients (Rosenberg et al., 2011).
Complementary research has been made to improve T-cell
adoptive therapies. Genetically engineered T cells are under study,
in order to manipulate the properties of the administered T-cell
population, such as proliferation and migration characteristics
(Liu and Rosenberg, 2001; Hinrichs et al., 2011). Also, T cells
have been genetically modified to have antitumor specificity by
introducing a T-cell receptor for a particular tumor, as previously
described in a review by Helmy et al. (2013).
DELIVERY STRATEGIES FOR IMMUNE CELL TARGETING AND
TRACKING
STRATEGIES FOR DC TARGETING
Since the role of DCs in inducing CTL immunity is well estab-
lished, several studies have been made in order to use DC-based
cancer vaccines in tumor immunotherapy.
Ex vivo
These vaccines use isolated CD14+ monocytes or CD34+ DC
precursors from an individual. After being isolated, these cells
are then cultured and differentiated in immature DCs (Romani
et al., 1994; Chapuis et al., 1997). The following process is TAA-
loading of DCs, which consists in adding proteins, peptides
or tumor lysates to its culture medium or through transfec-
tion. Additional maturation stimuli, such as CD40L or pro-
inflammatory cytokines, may be used to ensure DCs will be
able to induce a strong cellular immune response. Finally,
loaded mature DCs are administered back into the patient
by intravenous (i.v.), subcutaneous (s.c.), intradermal (i.d.),
intratumoral (i.t.) or intralymphatic (i.l.) route (Hamdy et al.,
2011).
The use of a tumor cell to stimulate DCs seems to induce a bet-
ter immune response, but it is limited by a possible induction of
autoimmune diseases, due to the lack of antigen specificity among
the undefined antigen found at cancer cell surface.
Whichever the type of antigen used to pulse DCs, although it
has been reported that this approach is safe and able to induce
CTL immunity, the clinical observed goal is low, possibly due to
the in vivo general complex interactions between immune cells
(Rosenberg et al., 2004).
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DC therapy involves the isolation, culture and stimulation of
patient’s monocytes and macrophages ex vivo using TAAs (Cho
et al., 2011). When administered back to the patient, antigen-
loaded DCs will bypass the in vivo uptake of tumor antigens.
DCs are already activated and therefore they are able to migrate
to the secondary lymph nodes wherein they will trigger T cells.
However, the relative short half-life of TAA-MHC complexes on
DC membrane surface, and the low percentage (3–5%) of DCs
that can migrate to the lymph nodes and contact with T cells can
contribute to the low rate of success of these vaccines (De Vries
et al., 2003; Hamdy et al., 2011). Also, being produced specifically
for a particular patient, ex vivo DC-based vaccines are a highly
complex, laborious, time-consuming and expensive approach.
Futhermore, the vaccine quality might depend on the clinic where
it is produced, once there are several variable parameters in the
process, such as dose of DCs and posology (Hamdy et al., 2011).
The type of DCs stimulated, antigen loading method and DC
maturation level are also important aspects to be characterized
to better understand the adjuvant role of DCs.
In vivo
To overcome the lack of clinical efficacy of ex vivo DC-based
cancer vaccines, it is extremely recommended to develop an alter-
native way to target antigens directly to DCs in vivo, which can
be achieved using peptide-based vaccines. These are mainly based
on MHCI peptides, which are simple to produce and administer,
and guarantee DC activation and expansion for prolonged peri-
ods of time (Figure 1) (Cheong et al., 2010; Silva et al., 2013).
However, the cytoplasmic delivery of the antigen is limited by low
membrane permeability and frequent destruction after intracellu-
lar entry, being their immunogenicity considerably lower than the
traditional vaccines. Hence, their association to potent adjuvants,
FIGURE 1 | Nanoparticulate cancer vaccines. (A) NPs are able to deliver
several TAAs and adjuvants simultaneously, enabling a coordinated
activation of DCs. NPs can also be functionalized in order to actively target
DCs in vivo, increase their cellular internalization and immunogenicity or
even target specific intracellular compartments. (B) NP-based cancer
vaccines can be targeted to DCs in vivo and after their internalization induce
the maturation of these cells. TAAs and adjuvants are simultaneously
released inside the same DC which guaranties its coordinated activation.
TAAs are presented trough MHC class I and class II molecules to CD8+ and
CD4+ naïve T cells which recognize the processed antigens through TCRs.
Activated CD8+ T cells differentiate into CTLs, which can destroy tumor
cells, and memory T cells, that are important to avoid recidivism and
metastasis. CD4+ T cells should differentiate in Th1 cells, which will
potentiate the action of CTLs and will also activate cells of the innate
immune system, such as NK cells, granulocytes and macrophages that play
a role in the tumor destruction process as well.
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as particulate vaccine delivery systems, or immunomodulatory
molecules is being widely investigated (Al-Hanbali et al., 2006;
Hillaireau and Couvreur, 2009; Sharp et al., 2009; Shahar et al.,
2010; Smith et al., 2012).
Numerous studies have demonstrated that these delivery plat-
forms could increase the uptake of antigens and adjuvants by
DCs, leading to better immune responses (Diwan et al., 2002;
Schlosser et al., 2008; Florindo et al., 2009a). In vivo DC-targeted
vaccines are able to deliver, within the same platform, both anti-
gens and additional stimuli (i.e., adjuvants) to the same cell in
its natural environment, enhancing and maximizing the out-
come (Kazzaz et al., 2006). Particulate delivery systems range
from micro and nanoparticles, liposomes, to virus-like particles
(VLPs). Unlike ex vivo DC vaccines, the clinical intervention
is limited to vaccine administration, sparing time in fastidious
cycles of blood withdrawal and in vitro cell culture. Also, it offers
on-shelf products, which can be produced at large scale with cost
reduction and increased quality.
NANOTECHNOLOGY-BASED APPROACHES AS IMMUNE CELL
TARGETED DELIVERY SYSTEMS
Nano-based systems have been described as platforms for tar-
geting and delivery of not only therapeutic agents, but also
nanodevices and analytical systems for theranostics. The range
of applications of nanosystems can include drug delivery, cancer
and gene therapy, as well as imaging and cell tracking through
biomarkers and biosensors (Rawat et al., 2006) (Supplementary
Material). Nanosystems have been used to increase the resolu-
tion of clinical imaging, with improved sensitivity and specificity,
leading to earlier diagnostics and real-time results. This may allow
the use of prophylactic measures, to avoid the progress of the dis-
ease or to greater efficacy of therapies, due to an earlier treatment
(Riehemann et al., 2009).
The development of nano-based systems has provided protec-
tion strategies for incorporated agents, such as biomolecules—
nucleic acids, peptides and proteins—which are generally quickly
degraded when administered in vivo. Therapeutic agents can be
embedded, encapsulated, or even adsorbed or conjugated onto
the nanosystems, which can be modified and associated to other
adjuvants to achieve an optimized release profile (Mahapatro and
Singh, 2011). Usual concerns about the administration of these
biomolecules have been eased, since lower doses are generally
used and a more restricted distribution is achieved (Rawat et al.,
2006). In fact, the widely recognized versatility of nanotechnology
strategies allows the accurate design of multifunctional nanocar-
riers. These, in turn, can be functionalized by ligands of different
natures to promote a targeted delivery of their cargo both at
cellular and subcellular level.
Nanocarriers can also potentiate the cytosolic delivery of
biomolecules as siRNA and miRNA, important gene expression
regulators, providing their escape from endo-lysosomal compart-
ments. miRNAs are short oligonucleotides (18–22 nucleotides)
and are involved in multiple pathways related to the devel-
opment and differentiation of cells, and in the pathogen-
esis of cancer, constituting a valuable target Chen et al.,
2014b; Gajos-Michniewicz et al., 2014). However, its in vivo
application demands the development of cell-specific delivery
approaches to promote their biological effect, which are currently
underexplored.
The modulation and regulation of the pathophysiology
dynamics at the molecular level has enabled nanomedicines
to achieve a disease control with an unprecedented precision.
Therefore, several nano-based systems composed by diverse
materials, and thus presenting different characteristics, have
been proposed and sorted in polymeric, lipid, metal and inor-
ganic nanocarriers (Figure 2). Among them, it is important to
underline liposomes, polymeric nanoparticles and micelles and
dendrimers.
Besides the strong demand to develop alternative thera-
peutic options to address unmet clinical needs, the novel
nanotechnology-based platforms have although important chal-
lenges, not only for industry but also for government agencies.
Efficacy and safety are evaluated on proof-of-concept studies, but
the manufacturing process must be robust by identifying all its
critical points and thus implementing “quality-by-design” (QbD)
concept or improved process analytical technologies (PAT).
Liposomes
Liposomes consist of self-assembled lipid bilayer membranes with
size ranging from 90 to 150 nm, which are formed by phospho-
lipids and cholesterol that enclose an aqueous core (Figure 3A).
Phospholipids are composed by hydrophilic heads and hydropho-
bic long tails. Thus, as previously described in several reviews,
their structure allows hydrophilic molecules to be incorporated
within the inner compartments, while the hydrophobic com-
pounds will be entrapped within the hydrophobic bilayer (Sahoo
and Labhasetwar, 2003; Aslan et al., 2013; Sharma et al., 2013).
The potential use of liposomes as delivery systems is based on
the fact that they provide a slow and sustained release, improv-
ing the accumulation of the entrapped molecules. Also, on their
ability to decrease cytotoxicity of incorporated molecules, since
they modulate the biodistribution and pharmacokinetics (Khan
et al., 2008; Sharma et al., 2013). Having in consideration their
biocompatibility, the biodegradability and ability to cross lipid
bilayers and cell membranes, liposomes have been proposed as
delivery platforms for vaccines, anticancer drugs and gene ther-
apy (Ewert et al., 2005). However, one of the major drawbacks
of conventional liposomes is the short circulation time, being
rapidly removed by mononuclear phagocytes of the reticular
endothelial system (RES). Stealth liposomes, or long-circulating
liposomes, have been developed to overcome this problem. They
consist in liposomes that are sterically stabilized, presenting thus
a prolonged half-life (Frank, 1993; Krishnamachari et al., 2011).
Regarding the success attained by liposomal platforms in the
clinic and advanced-stage clinical trials, several liposomal-based
delivery systems are nowadays offered as an anticancer strat-
egy, such as liposomal doxorubicin, cytarabine and cisplatin
(Abraham et al., 2005; Huwyler et al., 2008; Aslan et al., 2013).
The use of liposomes for doxorubicin delivery prevents the dam-
age of heart and renal healthy tissues that is usually induced by
the extreme toxicity of the drug (Abraham et al., 2005). Moreover,
doxorubicin has already been formulated in active targeted lipo-
somes for breast cancer therapy, using engineered peptide ligands
(Sharma et al., 2013). Other attractive approach is the use of
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FIGURE 2 | Examples of polymeric, lipid, and metal and inorganic nanocarriers.
liposomes as carriers for antisense oligonucleotides, as siRNA, in
cancer therapy (Tari et al., 1996).
Van Broekhoven et al. (2004) have reported a DC-targeting
vaccine, based on a liposomal formulation, as an outstanding
platform to induce a highly effective immunity against tumor cells
(Van Broekhoven et al., 2004). Preclinical studies of liposome-
DNA complexes have also been described, constituting an effec-
tive strategy to elicit anti-tumor immunity (U’ren et al., 2006).
The phase I clinical trial of a liposomal cancer vaccine for
breast, ovarian and prostate cancer has already been reported. It
has been proved that this peptide vaccine, which is intended to
elicit multi-functional T-cell responses, is safe and immunogenic
(Berinstein et al., 2012).
Additionally, liposomes have been studied as carriers for alter-
native bioorganic and biodegradable contrast agents, as glyco-
gen and poly-L-Lysine. With these liposomes, it was possible to
develop an in vivo multi-color magnetic resonance imaging for
lymph node mapping (Chan et al., 2014).
Polymeric nanoparticles (NPs)
Polymeric NPs are submicron-sized polymeric colloidal par-
ticles with excellent features as vehicle for the delivery of
drugs, biomolecules and genes (Panyam and Labhasetwar, 2003;
Mahapatro and Singh, 2011).
Polymer properties such as biocompatibility, low toxicity and
biodegradability have highlighted polymeric NPs as an interest-
ing delivery strategy. The chemical structure of the polymers
is easily modified, allowing the development of multifunctional
engineered systems. Nanoparticle size, shape and surface proper-
ties can also be tailored, as well as the degradation kinetics and
mechanical properties (Albertsson, 2002).
Polymeric NPs are usually highly stable and can easily entrap
and/or adsorb both hydrophilic and hydrophobic molecules with
good efficacy (Gelperina et al., 2005). The drug entrapment
protects molecules from degradation (Singh and Lillard, 2009).
Additionally, as nano-sized polymeric particles, these carriers are
easily transported through extra and intracellular barriers. As
a result, entrapped agents may be delivered site-specifically, for
instance in inflamed areas or tumors, after crossing the endothe-
lium (Prokop and Davidson, 2008; Singh and Lillard, 2009).
Two different types of polymeric NPs are usually considered:
nanospheres and nanocapsules (Figure 3B). Nanospheres consist
in a polymericmatrix in which the drug or cargo is homogenously
dispersed, whereas nanocapsules are vesicular systems formed by
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FIGURE 3 | (A) Liposomes are phospholipid and cholesterol self-assembled
bilayer membranes that enclose an aqueous core, where hydrophilic
molecules can be incorporated. Hydrophobic compounds can also be
incorporated in the lipid bilayer. Liposomes can be classified in (i) small
unilamellar vesicles (SUVs); (ii) large unilamellar vesicles (LUVs) and (iii)
multilamellar vesicles (MLVs), according to their size and lamellarity.
(B) Polymeric nanoparticles are submicron spherical entities composed by a
polymeric compact net than can either constitute a polymeric matrix—in the
case of nanospheres—or a polymeric wall surrounding a vesicular
core—nanocapsules. Nanoparticles can transport hydrophilic and hydrophobic
molecules either entrapped in the polymeric matrix or core, or adsorbed to
their surface. (C) Polymeric micelles are self-assembled spherical
nanocarriers formed by amphiphilic block copolymers. In aqueous medium,
the block copolymers arrange themselves in a disposition where the most
hydrophobic parts of their chains form a hydrophobic core—where
hydrophobic molecules can be incorporated –, and the most hydrophilic
regions of the polymer chain are displayed outoward. (D) Dendrimers are
hyperbranched nanocarriers formed by a central core, branching monomers
and functionalized peripheral groups. Dendrimer synthesis can start from the
core element (divergent polymerization) or from the peripheral branching
units (convergent polymerization), resulting in a structure with a hydrophilic
surface and a hydrophobic central core. Molecules can be transported by
dendrimers either incorporated in the core and branches, either conjugated to
the terminal groups.
a polymer wall that surrounds a core containing the cargo (Singh
and Lillard, 2009).
Several methods have been used to produce polymeric
nanoparticles. Some of the most studied are spray-drying, salting
out, nanoprecipitation and emulsion-based methods, The latter,
in particular, lies on an emulsification process with the removal
of organic solvents used for polymer dissolution, by extrac-
tion or evaporation. The emulsified organic drops containing
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the polymer originate nanoparticles, when the organic solvent is
eliminated (Lassalle and Ferreira, 2007).
Nevertheless, it is important to bear in mind that the cho-
sen method will influence the characteristics of the obtained NPs,
such as the size and the surface. Besides, it is crucial to have a great
knowledge about the different experimental variables, in order to
achieve the intended formulation characteristics (Gorner et al.,
1999; Lassalle and Ferreira, 2007).
A large number of polymers from different origins have
already been described as useful materials for polymeric NP pro-
duction and used in preclinical studies. Polymers can be from
natural origin, as chitosan, or synthesized, as polylactic acid
and poly-lactic-co-glycolic acid (PLGA) (Krishnamachari et al.,
2011; Mizrahy and Peer, 2012). Particulate adjuvants, such as
PLGA and PCL NPs, have generated a lot of interest due to
their biodegradability, biocompatibility and mechanical strength.
(Danhier et al., 2012) has nicely reviewed the main properties
and applications of PLGA-based nanocarriers. These NPs can also
act as adjuvants, maintaining the antigenicity and immunogenic-
ity of encapsulated proteins. In fact, PLGA, used for decades in
humans, is the most studied polymer for vaccine formulation
and it was shown to increase antibody and cellular responses
to antigen-loaded PLGA NP (Johansen et al., 2000; Shen et al.,
2006; Chen et al., 2014a). PCL has a great potential for devel-
oping antigen controlled release matrices by its low degradation
rate, hydrophobicity, good drug permeability, in vitro stability
and low toxicity. The adjuvant effect of PCL NPs to induce
immune responses against an infectious disease was previously
confirmed by several studies (Benoit et al., 1999; Florindo et al.,
2008, 2009b; Labet and Thielemans, 2009). If the encapsulated
antigen fails to induce DC activation, these NPs can be mod-
ified with maturation signals at their surface for direct ligand-
receptor interaction, as mannose receptor is overexpressed at DCs
and macrophage cell surface. Chitosan NPs, for instance, are
an interesting strategy for gene delivery, namely small interfer-
ing RNA (siRNA). As chitosan is positively charged, electrostatic
interactions occur with negatively charged siRNA, and thus the
biomolecule is safely carried to its in vivo target (Aslan et al.,
2013).
Nanocarriers produced using polypeptide-based polyanionic,
zwitteronic and polycationic polymers (e.g., polyglutamic acid,
polyarginine) have also been described (Christian et al., 2009).
These are endosomolytic polymers and have been used to pro-
mote the cytosolic delivery of these biomolecules. Although clin-
ical trials with peptide-based cancer nanovaccines have shown
little success, more recent research has been developed to improve
them, using novel polymeric NPs systems.
It has been reported that PLGA NPs loaded with melanoma
antigens can elicit effective anti-tumor activity by CTLs in vivo
(Zhang et al., 2011; Ma et al., 2012). DC-targeting chitosan NPs,
carrying IL-12, were also used in a preclinical study. The admin-
istration of this nanovaccine in an animal model resulted in sup-
pression of tumor growth and increased induction of apoptosis
(Kim et al., 2006).
Regarding immune cell tracking, biodegradable PLGA NPs
have been used in a combined multimodal imaging strategy
for a DC-targeting nanovaccine. Superparamagnetic iron oxide
particles and a fluorescently labeled antigens were incorporated
within the same nanosystem, allowing not only the analysis and
quantification of NPs uptake, but also the subcellular tracking of
NPs (Cruz et al., 2011).
Polymeric micelles
Polymeric micelles are self-assembled spherical nanocarriers
formed by amphiphilic block copolymers in aqueous medium
(Figure 3C). A hydrophobic core and a hydrophilic surface com-
pose these structures, and their size ranges from 10 to 100 nm
(Torchilin, 2001; Jhaveri and Torchilin, 2014).
Polymer micelles have been investigated as delivery systems for
poorly water-soluble/hydrophobic drugs due to the hydrophobic
core. It has been shown that micelles can enhance the bioavail-
ability of hydrophobic molecules, which is reassured because
they protect the drug from in vivo degradation (Torchilin, 2001;
Jhaveri and Torchilin, 2014). Other advantages of polymeric
micelles are the low toxicity, the prolonged circulation time and
good levels of accumulation in tumor areas (Ganta et al., 2008).
In an experiment with nude mice xenograft model, PLGA-PEG
polymeric micelles have shown increased tumoral uptake (Yoo
and Park, 2004).
Novel pH-responsive polymer micelles formed by an
N-(2-hydroxypropyl) methacrylamide corona and a propylacrylic
acid (PAA)/dimethylaminoethyl methacrylate (DMAEMA)/butyl
methacrylate (BMA) core have already been investigated for
antigen trafficking modulation in DCs. The results showed
that this nanosystem facilitates the antigen delivery to DCs in
the lymph nodes and enhances CD8+ T cell responses, being
thus a potential carrier for cancer vaccines (Keller et al., 2014).
Also, micelles formed by DMAEMA and pyridyl disulfide ethyl
methacrylate (PDSEMA), carrying both CpG ODN and protein
antigens, have shown to elicit and increase cellular and humoral
immune response by modulating and stimulating antigen
cross-presentation, as summarized by Wilson et al. (2013).
Dendrimers
Dendrimers consist in hyperbranched spherical nanocarriers
formed by a central core, branching monomers and functional-
ized peripheral groups. Dendrimers can be produced by conver-
gent or divergent polymerization of branching units, resulting in
a structure with a hydrophilic surface and a hydrophobic central
core (Figure 3D) (Lee et al., 2005). Their main physicochemi-
cal features are low viscosity, hyperbranched molecular topology,
marcromolecular size, high density of chemical functionality and
multiple end groups that can be chemically functionalized (Lee
et al., 2005). Also, the depolymerization of dendrimers can be tai-
lored in order to control the release profile of the loaded agents,
as described in a review by Wong et al. (2012). Besides vaccines,
therapeutic and targeting carriers, dendrimers have also been
reported as diagnostic tools due to their ability to protect imag-
ing agents, decreasing its toxicity and enhancing specificity (Yang
et al., 2009).
Nowadays, the most described family of dendrimers is the
well-studied polyamidoamine (PAMAM). Poly(propyleneimine)
and peptide dendrimers, such as poly(L-glutamic acid)
dendrimers, have also been studied (Nanjwade et al., 2009).
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Linear poly(glutamic acid) is a poly(amino acid) polymer with
considerable potential for antigen delivery to DCs, and adjuvant
properties for DC maturation, able to induce CTLs (Yoshikawa
et al., 2008). Additionally, it has been shown to be safe for use
in clinic (Chipman et al., 2006) providing the necessary safety
profile for human use. These glycopeptide dendrimers have
shown promise for antitumor and antiviral prophylactic or
therapeutic vaccines, as well as antiviral agents (Niederhafner
et al., 2008). Several formulations have reached clinical trials as
vaccines against breast (Gilewski et al., 2007), prostate (Slovin
et al., 2003), and small cell lung cancers (Krug et al., 2004) with
encouraging results. Even though, further investigation must
be done in order to guarantee the long-term safety, before they
become clinically available (Aslan et al., 2013).
INFLUENCE OF NANO-BASED TECHNOLOGY PROPERTIES IN CELLULAR
UPTAKE
Arguably, the weakest link in preclinical experimentation of nan-
odelivery systems is the continued failure to document dynamic
processes (over time) using complex biosystems as models, i.e.,
a systems biology approach. The outcome of different classes
of nanomedicines under preclinical and clinical evaluation has
demonstrated that their main biological consequences of cellular
or subcellular targeting and access are closely related to materials
intrinsic properties (Ehmann et al., 2013).
The uptake of TAAs, carried within nano-platforms, by DCs
is in fact influenced by several particulate physicochemical prop-
erties. Size, shape, surface charge, hydrophobicity and recep-
tor interactions are generally underlined (Foged et al., 2005;
Bachmann and Jennings, 2010). Particulate vaccines, such as
whole-cell vaccines, virosomes, VLPs or formulated delivery plat-
forms such as liposomes, micro and NPs have great surfaces
with electrostatic or receptor-interacting properties, leading to
an increased interaction when compared to soluble antigens
(Bachmann and Jennings, 2010). Also, it has been reported that
particulate size can direct the DC subset target. However, the
ideal dimensions of NPs for APC uptake are still under discus-
sion. In fact, small size platforms (<200 nm) may drain freely
to LNs, being thus taken up by LN-resident DC subsets such as
CD8α+, which seems an advantage for cancer immunotherapeu-
tic approaches. However, delivery systems greater than 200 nm
appear to be taken up by circulant monocytes, which differenti-
ate after particle uptake andmigrate to LNs afterwards (Manolova
et al., 2008). According to Foged and colleagues, NP size should be
0.5μm or less to be quickly and efficiently incorporated by DCs
(Foged et al., 2005).
Size
NP size appears to influence the cellular uptake mechanism and
the endocytic pathway of NPs, dictating their ultimate intracellu-
lar fate and thus overall biological effect. NPs may be assimilated
by receptor-mediated endocytosis, clathrin-dependent and/or
caveolae-mediated, and phagocytosis, or through a receptor
independent mechanism—macropinocytosis. Particulate systems
with a larger diameter (>0.5μm) tend to be assimilated through
macropinocytosis and/or phagocytosis by some specific cells, as
macrophages and Langerhans cells in the skin. Smaller particles
usually enter the cell through endocytosis. NPs with size<150 nm
are generally taken by cells via classic receptor-mediated endo-
cytosis (clathrin-dependent) or endocytosis caveolae-mediated if
ranging from 50 to 80 nm (Pelkmans and Helenius, 2002). These
NPs with size equivalent to viruses are usually able to initiate
a virus-like immune response with activation of CTL and Th1.
On the other hand, larger particles normally generate a similar
immune response to that induced by bacteria, with Th2 activation
and antibody production (Xiang et al., 2006).
Shape
Besides size, it has also been reported that particle shape may
influence cellular uptake and biodistribution. Although it has
been suggested non-spherical particles may be valuable for their
increased blood circulation time, due to reduced phagocytosis by
unspecific cells, they also demonstrated decreased cellular uptake,
when compared to spherical NPs. According to Gratton et al., rod-
shaped NPs show the highest uptake performance, followed by
spheres, cylinders and finally cubical NPs (Gratton et al., 2008).
Surface charge
NP surface charge also seems to play an important role in their
particle internalization and thus will also determine the nature of
the induced immune response (Xiang et al., 2006). As cell mem-
brane charge is negative, positively charged molecules/systems
will show high affinity to it. After cellular uptake, it has been
observed that negatively charged or neutral NPs tend to localize
within lysosomes, whilst positively charged NPs showed ability
to escape from these. Cationic NPs were found in the perin-
uclear area and have been reported as effective for uptake by
macrophages and DCs (Thiele et al., 2003; Yue et al., 2011). On
the other hand, the interaction of those delivery systems with
cell depends on multiple factors and some studies have reported
the presence of neutral NP at endoplasmic reticulum, suggest-
ing their ability to escape degradation at lysossomal/endossomal
compartment (Zhou et al., 2014).
NANOCARRIERS FOR TUMOR AND IMMUNE CELL TARGETING
Passive targeting
Passive targeting results from the transport of nano-based sys-
tems across the abnormal leaky vasculature of tumors, into the
tumor interstitium or cells, by their movement within fluids—
convection—or by passive diffusion. Whereas convection is
observed for larger molecules, compounds with low molecular
weight cross the membranes by diffusion, depending only on the
concentration gradient (Iyer et al., 2006; Danhier et al., 2010).
As blood vessels architecture and its regulation are com-
promised, caused by unpaired angiogenesis, nanocarriers tend
to accumulate selectively in tumor interstitium due to the
“Enhanced Permeability and Retention (EPR) effect.” The
increased size of gaps in endothelial cells creates pores rang-
ing from 10 to 1000 nm, which along with the poor lymphatic
drainage, contributes to the EPR effect, that was first described
by Matsumura and Maeda (1986); Yuan et al. (1995); Danhier
et al. (2010). This effect has become very important for the
design of targeted nanocarriers for cancer therapies. It has been
reported that NP levels of accumulation in tumor interstitium
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are 10–50-fold higher than in normal tissues, leading to improved
therapeutic efficacy and less side effects (Iyer et al., 2006; Danhier
et al., 2010).
Active targeting
Nanotechnology-based strategies have been explored as platforms
for drug delivery, cancer vaccination and/or diagnosis, due to
their capacity for overcoming biological barriers and to modulate
payloads’ intracellular trafficking. These nanoparticulate systems
present a good potential for site-selective delivery by binding
recognition ligands to NP surface, which can enhance NP endocy-
tosis, influencing their intracellular trafficking and thus inducing
prolonged effects (Danhier et al., 2010).
Surface functionalization of nano-based systems (Figure 4)
has been used to improve tissue and cell surface antigen targeting,
thus moderating non-specific distribution and prolonging the
blood circulation time of nano-based systems (Alexis et al., 2008).
PEGylation is a widespread strategy to improve the half-life
time of nanocarriers, through steric stabilization and “stealth”
properties. It relies on the introduction of poly(ethylene glycol)
(PEG) molecules by conjugation, grafting or adsorption onto
the surface of nanosystems (Figure 5). The terminal groups of
PEG chains also present very suitable moieties to attach func-
tional ligands and attain active-targeted carriers (Freichels et al.,
2012). The conjugation of antibody fragments to PEG ends,
using disulfide bonds, may consist in an interesting strategy to
develop platforms for active targeting (Brocchini et al., 2008).
D-α-tocopheryl polyethylene glycol succinate (TPGS) has been
reported as an alternative to PEG (Pan and Feng, 2008).
Active-targeted nanosystems are based on the design of
nanocarriers with bioactive ligands placed onto their surface
or periphery. They will be recognized by overexpressed molec-
ular patterns at the tissues/cells intended to target, facilitating
NP recognition and subsequent receptor-mediated endocytosis
(Figure 6) (Cheng et al., 2007; Kumar et al., 2009; Danhier et al.,
2010; Aslan et al., 2013; Nicolas et al., 2013; Wang et al., 2013a;
Gao et al., 2014). Surface modifications represent an outstanding
tool for cell targeting allowing a specific contact of nanopartic-
ulate systems with critical immune cells, as evidenced in Stephan
et al. (2010). For example, the ligand DEC-205 is highly expressed
by CD8+DCs, cells particularly efficient at “cross-presenting”
exogenous antigens on MHCI, constituting a highly relevant
pathway for the development of a cytolytic immune response.
Moreover, recent studies have indicated that the triggering of
CD40 on APCs can lead to CD8 T-cell effectors, without the need
of common stimulation by MHCII-related Th cells via CD40 lig-
ands (Vonderheide et al., 2013). Mannose receptors at DCs are
also associated to ligand internalization and further processing
and presentation by immune cells, leading to a more extensive
immune response (Lu et al., 2007; Carrillo-Conde et al., 2011;
Silva et al., 2013).
These ligands, such as peptides, antibodies and antibody frag-
ments, carbohydrates and even vitamins, may be either attached
before the nanocarrier production or afterwards. Liking ligands
FIGURE 4 | Examples of NP functionalization. NPs can be
functionalized differently in order to attain distinct goals. PEG or TGPS
functionalization provide stealth properties to NPs, avoiding capture by
phagocytic cells and increasing their circulation time. Functionalization
of NPs with imaging agents, such as fluorescent probes, radionuclides
or contrast agents (e.g., gold or magnetic NPs), provide applicability
of NPs to diagnostic, theranostic or even in vivo real-time imaging.
The immunogenicity of NPs can be increased for immunotherapy or
prophylactic vaccination. Different molecules can be used for that
propose, such as PAMPs (several carbohydrates, lipids or nucleic
acids) or immunogenic polymers (e.g., chitosan, alginate, poloxamers).
Specific tissue and cell targeting can be achieved through the
functionalization of NPs with antibodies directed to specific or
overexpressed antigens. Cell-penetrating peptides can improve NP
internalization. pH-sensitive coatings allow drug release in specific
tissues or intracellular compartments in a pH-dependent manner.
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FIGURE 5 | The stealth effect from NP functionalization with PEG. (A)
Particulate foreign entities in body fluids are promptly covered with
opsonins, such as the immunoglobulins IgG and IgA and the complement
proteins C3b C4b, in a process called opsonization. Opsonins mark the
particulate entity to phagocytosis through their recognition by Fc receptors
on phagocytic cells, such as macrophages. (B) Functionalization of NPs
with PEG by grafting, conjugation or adsorption—note the
“mushroom-like” (a) or “brush-like” (b) configuration of PEG
chains—provides steric stabilization and stealth properties, preventing the
adsorption of opsonins at the surface of nanoparticles. PEG hydrophilicity
attracts water molecules to particle surface avoiding the adsorption of
opsonins at NP surface, rendering them “invisible” to phagocytic cells.
prior to nanocarrier production may be advantageous, so that the
conjugation yield of the ligand to the polymer can be assessed
and controlled. Nanocarriers can be thus produced with a well-
characterized (co)polymer and the density of ligands on their
surface can be tailored. Physicochemical properties of the poly-
mers must be evaluated after ligand conjugation, because the
hydrophilic/hydrophobic balance may be altered, particularly if
macromolecules are linked (Betancourt et al., 2009; Sperling and
Parak, 2010; Nicolas et al., 2013).
The strategy of attaching ligand molecules after nanocarrier
production is usually applied, when antibodies, proteins and
polypeptides are chosen as targeting agents. As some organic sol-
vents are generally used in the preparation of nanosystems, this
method is preferred to avoid denaturation of the secondary struc-
ture of the ligands. Also, since they are bulky molecules, they will
disturb the hydrophilic/hydrophobic balance which can difficult
the method of nanocarrier production (Nicolas et al., 2013). The
drawbacks of this approach are related with subsequent purifi-
cation of the formulation and its characterization. The processes
frequently used for purification, such as centrifugation, filtration
and dialysis, may degrade or alter the nanosystems. Additionally,
it is usually difficult to prove that the ligand is covalently linked
to the surface of the nanocarrier and not only adsorbed (Nicolas
et al., 2013).
Ligation strategies for functionalization. Several pathways have
been developed to attach ligands onto nanosystems surface,
such as the carbodiimide strategy, the Michael addition pathway,
the biotin–streptavidin approach and the Copper-catalized liga-
tion method (Betancourt et al., 2009; Nicolas et al., 2013). The
native terminal groups of some polymers or specific moieties,
introduced through chemical modifications, are generally used to
apply these schemes of functionalization. For instance, carboxylic
acid terminals in aliphatic polyesters and poly(ethylene glycol)
(Betancourt et al., 2009).
The most used scheme is based on the carbodiimide chem-
istry. It relies on the coupling of a molecule containing a ter-
minal amine group with another with an N-hydroxysuccinimide
(NHS) ester end or an end group that can be easily esterified
to NHS moiety (Betancourt et al., 2009; Nicolas et al., 2013).
The Michael addition pathway is based on the thiol-maleimide
coupling. Maleimide-polymers are used to produce nanocarri-
ers, which are then decorated with thiol-containing targeting
agents (Betancourt et al., 2009; Nicolas et al., 2013). However,
the presence of native thiol groups in some molecules, as pro-
teins and peptides, is usually low (or absent in some cases) and
many are hard to access. To overcome this, disulfide bonds can
be reduced in thiol groups or heterobifunctional cross-linking
agents may be used (Nicolas et al., 2013). The biotin–streptavidin
approach utilizes a strong non-covalent biological interaction
between biotin and avidin (Betancourt et al., 2009; Nicolas et al.,
2013). Still, for this strategy, a targeting agent is usually chem-
ically bound to avidin, which is a bulky glycoprotein that may
then obstruct the interaction ligand-receptor, essential for target-
ing (Betancourt et al., 2009). The Copper-catalized ligation is a
highly efficient method, based on a cycloaddition reaction that
fits in the “click chemistry” class of reactions. The chemical reac-
tion is developed in mild conditions and with little or absent
byproducts. The major disadvantage of this approach is the elim-
ination of the Cu-based catalyst used for the reaction (Nicolas
et al., 2013).
Functionalization of nanosystems for immune cell targeting.
Extensive research has been made regarding cell surface receptors
in immune cells, the so-called PRRs. PRRs recognize pathogen-
associated molecular patterns (PAMPS) and are involved in
several stages of the immune response, from its initiation and
proliferation, to its execution (Kumar et al., 2009). Different
types of molecules may act as PAMPs, known as “danger sig-
nals,” for instance lipids, lipoproteins, proteins, carbohydrates
and nucleic acids. The recognition of PAMPs by PRRs triggers
immune responses by activating multifactorial signaling path-
ways. This leads to the induction of inflammatory responses
mediated by several cytokines and chemokines (Kumar et al.,
2009).
Several classes of PRRs have been reviewed, such as TLRs,
retinoic-acid inducible gene (RIG)-like receptors (RLRs),
nucleotide oligomerization domain (NOD)-like receptors
(NLRs), DNA receptors (cytosolic sensors for DNA), scavenger
receptors, and C-type lectin receptors (CLRs) (Kumar et al.,
2009; Carrillo-Conde et al., 2011; Shen et al., 2013; Silva et al.,
2013). In mammals, the most studied PRR class is the TLRs class.
TLRs are predominantly expressed by APCs, as DCs, but they are
also found on cells of the adaptive immune system, such as in
αβT cells, regulatory T cells, and γδT cells, as well as NKT cells
(Wesch et al., 2011). Through TLR activation, both the innate
and the adaptive immune responses can be engaged, either by
direct activation of TLRs with their ligands on T and B cells, or by
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FIGURE 6 | Ligand-cell interaction and NP internalization. NPs can be
functionalized with different ligands to increase cell targeting and NP
internalization. (A) Functionalization of NPs with antibodies allows the
targeting of antigens exclusively expressed or overexpressed by target cells
(e.g., anti-CD205 antibody to target CD205 on DCs or anti-HER2 antibody to
target HER2 on breast cancer cells). (B) In order to target DCs, NPs can be
functionalized with molecules that mimic PAMPs, normally carbohydrates,
nucleic acids or lipids, which are recognized by PRRs expressed by DCs. For
instance, mannose or fucose residues are recognized by the mannose
receptors—a C-lectin receptor. Bacterial lipopolysaccharide or flagellin target
TLR4 and TLR5 on DCs, respectively. (C) Cell-penetrating peptides are small
amino acid sequences normally used by viruses or bacteria to facilitate
cellular invasion by those pathogens and can be used to increase the
internalization of NPs. Functionalized NPs see their internalization by target
cells increased essentially by two mechanisms: induction of endocytosis
upon ligand-receptor binding, which happens to NPs functionalized with
ligands such as antibodies, PAMPs or some penetrating peptides that induce
receptor-mediated endocytosis (e.g., integrins) or (D) through direct cell
penetration across the plasma membrane (e.g., antimicrobial peptides or
histidine-rich peptides) (E) or both (e.g., HIV TAT peptide).
indirect mechanisms involving TLR-activated DCs (Silva et al.,
2013). C-type lectin receptors (CLRs) belong to another class of
PRRs expressed by APCs. This receptor family is characterized by
the presence of domains that bind to carbohydrates (Van Kooyk,
2008). CLRs are specific receptors particularly engaged in the
internalization of antigens. CLRs enable the intracellular uptake
and processing of antigens, as well as influence their cytosolic fate
and the loading on MHC class I and II (Unger and Van Kooyk,
2011).
Regarding the involvement of PRRs in several strategic
immune pathways, the design of nano-based systems for immune
cell targeting can be extremely interesting. Not only because a
more specific delivery can be achieved, but also because the cellu-
lar internalization of the targeted nanosystem can be modulated
and potentiated. Additionally, the attachment of PRRs ligands
on the surface of nanocarriers may boost their immunogenic-
ity, which can be an outstanding strategy for the development of
vaccines, since it allows the incorporation of an antigen and the
“danger signal” in the same platform (Silva et al., 2013).
NANOCARRIERS FOR IMAGING APPROACHES
The importance of a deeper knowledge of the dynamic cancer
immunological processes has long been realized. The study of
these processes in vivo, with living cells and the whole organism,
is essential to answer this issue more accurately. Cancer disease
processes will be better understood and thus improved therapies
can surely be developed. For the visualization of these biological
dynamic processes in vivo, methods have to provide a real-time
in situ fast response, as well as be non-invasive and with high
sensitivity and stability (Wang et al., 2013b).
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The use of targeted nanoplatforms for this purpose enables
a more specific interaction with the intended target, with min-
imal interference to the biological system (Ballou et al., 2004).
Additionally, nanocarriers may be functionalized with single or
multiple ligands, which may be important for the design of
complex experiments. The targeting of ligands may enhance the
selective recognition of the nanodelivery systems by cells, facili-
tating their endocytosis. This will allow nanosystems to be used as
non-invasive localization, monitoring and assessment platforms,
for instance, for site-specific intracellular characterizations and
real-time tracking (Ruan et al., 2007).
Fluorescence imaging techniques
Fluorescence imaging is an optical imaging method based on
the excitation/emission of molecules (Cai and Chen, 2007). The
use of fluorescent molecular probes—as fluorescent dyes and flu-
orescent proteins—has been widely applied in the labeling of
biomolecules, cells and tissues. Although these probes are already
used in vivo, for instance in retinal angiography and visualiza-
tion of arteries, they are unsuitable for real-time imaging assays,
regarding their low photostability and sensitivity at the cellular
and molecular levels (Santra and Malhotra, 2011). The applica-
tion of fluorophores in real-time in vivo imaging has also been
limited by the high absorption of optical signal by tissues and
body fluids in the UV and visible wavelength. The light scatter-
ing caused by tissues that attenuate the optical signal and the
tissue auto-fluorescence that influences the background signal is
also a limitation (Santra and Malhotra, 2011). Additionally, some
fluorescent probes may be toxic for cells and body (Li et al.,
2013). Several NP-based strategies have been proposed to over-
come the limitations of fluorescent dyes for real-time in vivo
imaging (Supplementary Material) (Santra and Malhotra, 2011;
Wang et al., 2013b).
Fluorescent-labeled NPs are more stable in the body and
increase the detection sensitivity and photostability. In the same
platforms, a great number of probe molecules can be incor-
porated, in opposite to a single conventional molecule. Also,
in NPs, fluorescent dyes can be protected from quenching and
degradation (Santra and Malhotra, 2011; Wang et al., 2013b).
The most extensively studied nanosystems for fluorescence
imaging are quantum dots (QDs) (Cai and Chen, 2007), inor-
ganic fluorescent NPs that can be based on metallic or semicon-
ductor materials, such as CdSe and CdTe (Ballou et al., 2004).
As reviewed by Cai and Chen, in ideal conditions, QDs can
have better properties than organic fluorescence probes. These
include high resistance to degradation and photobleaching, high
quantum yields, high molar extinction coefficients, continuous
absorption spectra covering from UV to near-infrared, long flu-
orescence lifetimes (>10 ns), narrow emission spectra and very
long effective Stokes shifts (Cai and Chen, 2007). QDs have been
used for innumerous applications, from cell tracking (Voura et al.,
2004) to mapping of sentinel lymph nodes (Ballou et al., 2007).
QDs can be used to identify several ligands in the same exper-
iment, using multiple colors and intensities to detect different
structures (Ballou et al., 2004). The potential use of DC-targeting
QDs as both fluorescent NPs for in vivo and in vitro imaging,
and antigen-delivery system has also been investigated. In this
study, it was proved that QDs display promising properties for
combined priming and immunoimaging of DC (Sen et al., 2008).
Functionalization and modifications of the surface of QDs with
PEG chains and ligands for active targeting, such as peptides and
antibodies, have been under research to improve the application
of these nanosystems in the biomedical field (Ballou et al., 2007;
Cai and Chen, 2007). QD conjugates are already commercially
available for immunospecific labeling (Ballou et al., 2004). Thus,
the development of multifunctional nanoplatforms holds a great
promise for the future of biomedicine, since it will be possible to
combine simultaneously both diagnosis and therapy in the same
nanostructure (Kim et al., 2008a).
Several other groups have suggested the use of silica-based
NPs (siNPs) as an interesting strategy to perform imaging assays
using fluorescence (Santra et al., 2005; Kim et al., 2008a; Wang
et al., 2013b). siNPs have been used for high sensitive and spe-
cific in situ labeling and tracking of cell surface receptors (He
et al., 2004, 2007). Relying on the affinity of antigen-antibody or
ligand-receptor interactions, NPs were functionalized with anti-
bodies and ligands and applied as an immunediagnostic method
(He et al., 2002). siNPs have also been used as a non-invasive
tool for intracellular labeling, tracking and sensing in living cells,
contributing with novel information about dynamic biological
processes of subcellular structures, such as lysosomes and endo-
somes (Shi et al., 2010). Finally, siNPs were applied to better
understand the biodistribution and fate of NPs, in vivo (Wang
et al., 2013b).
Molecular imaging techniques
The key role of immune cells in the development of future
immunotherapeutic approaches against chronic pathologies,
mainly cancer diseases, has fostered the design and optimiza-
tion of different real-time imaging techniques, avoiding the classic
ex vivo histologic analysis (Kircher et al., 2011; Ahrens and Bulte,
2013; Liu and Li, 2014). In fact, most of the information obtained
for immune cell tracking has arisen from optical and confocal
microscopy and flow cytometry. Two-photonmicroscopy allowed
the observation of different immune cells in their biological envi-
ronment at real time (Progatzky et al., 2013). However, despite
being a powerful tool to observe these highly motile cells and
characterize their interaction with native environment, this imag-
ing technique is unsuitable for detection of deeper events due to
tissue opacity (Dzhagalov et al., 2012).
Bioluminescence imaging techniques, on the other hand,
enable deeper tissue penetrations while tracking immune cells
in vivo. Even though, it is one of the most commonly used tech-
niques for immune cell tracking in vivo, allowing whole-body
non-invasive tomography. This technique is only useful for pre-
clinical studies in small animals, due to the limits related to the
attenuation of light in tissues (Kircher et al., 2011).
All near-infrared (NIR) multiphoton microscopy methods are
potential techniques for deep tissue imaging but further studies
are needed to better characterize the capabilities of these NIR-
excitation techniques and background reduction (Joshi et al.,
2013).
Magnetic resonance imaging (MRI), ultrasound, positron
emission tomography (PET) (Yaghoubi et al., 2009), single
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photon emission tomography (SPECT) and X-ray computed
tomography (CT) are the imaging techniques approved for med-
ical applications (Bernsen et al., 2014). PET and SPECT are
high-sensitivity and low-resolution techniques, while MRI and
CT provide high-resolution images (Liu and Li, 2014). However,
the use of radionuclide-based techniques, as PET and SPECT,
has brought questions regarding their safety (Laskey et al.,
2010). In addition, their combination with additional meth-
ods is fundamental to obtain an anatomical image. Therefore,
the combination of these different imaging modalities consti-
tutes a multimodality imaging method that has been explored
in preclinical and clinical development, including SPECT/CT and
MRI/PET (Naumova et al., 2014).
Among these techniques, MRI is the most versatile and sensi-
tive method allowing the study of immune cell morphology and
function (Ahrens and Bulte, 2013). In fact, innovative and safer
techniques are emerging from the use of different biocompatible
cell labeling probes and MRI to obtain high-resolution images
without using ionizing radiation (Sosnovik and Nahrendorf,
2012; Thu et al., 2012). The signal used for MRI arises from the
water protons (1H) or different fluorinated molecules (e.g., 19F)
under a static magnetic field and after pulsed by a radio-frequency
radiation, which alters the equilibrium of their nuclei. The MRI
signal will then result from a transient voltage determined by the
properties of labeled tissue (Ahrens and Bulte, 2013).
This non-invasive and safe imaging technique has been
expected to track immune cells in vivo, enabling the characteri-
zation of their biodistribution and fate. MRI also seems suitable
for the detection/quantification of surface markers and secreted
factors resultant from biological processes occurred in vivo at a
particular disease stage (Lu et al., 2013; Naumova et al., 2014).
The rapid evolution in this field, advanced by the potential effi-
cacy of next-generation cellular-based therapeutic approaches
(e.g., immunotherapy and stem cell-based therapy), will certainly
make this method a crucial tool to follow detailed biological and
immunological processes in vivo.
The successful application of these in vivo cell-tracking tools
can potentially optimize image-guided diagnostics and the overall
efficacy of different therapeutic options. Particularly, those based
on the modulation of endogenous cells support the selection of a
specific treatment, the choice of the best administration route and
also the use of a correct dose for each patient (Ahrens and Bulte,
2013).
Different exogenous cell-labeling probes have been explored
but superparamagnetic iron oxide (SPIO) nanoparticles and per-
fluorocarbon (PFC) nanoemulsions seem to be the most promis-
ing for those advanced MRI-based techniques (Supplementary
Material). Moreover, these are the unique in vivo MRI cell-
labeling techniques approved for human clinical trials, and thus
will be further discussed (Ahrens and Bulte, 2013).
Nano-based systems for MRI real-time tracking of immune
cells. Different nanosystems (Supplementary Material) have been
developed for MRI-based in vivo cell tracking, but the nega-
tive contrast agents based on SPIO and PFC constitute the most
explored ways to control MRI signal and consequent detec-
tion (Hawrylak et al., 1993; Bulte and Kraitchman, 2004). SPIO
contrast agents are small particles composed by ferrous and fer-
ric oxides, usually coated by dextran. Even though, these ionic
NPs have been modified by other biodegradable polymer (e.g.,
chitosan, PEG, siloxanes, polyaniline, glyceryl monooleate) and
labeled with targeting moieties to potentiate their delivery to
certain tissues (Supplementary Material) (Shubayev et al., 2009;
Dilnawaz et al., 2010). These MRI-based contrast agents strongly
perturb the magnetic field of the region in which they are embed-
ded. The water molecules will sense that alteration in the mag-
netic field and the resultant loss of signal will lead to a dark image
(Ahrens and Bulte, 2013). On the other hand, fluorinated-based
probes directly label targeted cells and thus the MRI signal is
dependent on the number of fluorine atoms and labeled cells,
which can be observed in their biological environment (Srinivas
et al., 2012).
The labeling of cells using these nano-based systems can be
performed ex vivo or in vivo, through their direct administra-
tion in the body. The labeling of immune cells ex vivo with
SPIO NPs has been explored to track and clarify migratory pat-
terns of diverse immune cells, as NK (Daldrup-Link et al., 2005),
cells from T lineage (Kircher et al., 2011), and DCs (De Vries
et al., 2005; Rohani et al., 2011) used during immunotherapeu-
tic cancer approaches. Innovative immunotheranostic strategies
under development combine these metal ion-based NP with tar-
geted nanoparticulate cancer vaccines. One interesting study has
shown multifunctional iron oxide NPs formulated in order to
deliver carcinoembryonic antigens to DCs and be detected by
MRI (Cho et al., 2011). Alternatively, some SPIO NPs have been
developed to label DCs membranes by modifying their surface
with CD11c antibodies, promoting receptor-mediated endocyto-
sis (Ahrens et al., 2003; Yu et al., 2012). Despite being a promising
approach against cancer disease, their clinical translation is still
unclear.
The ex vivo labeling of a DC-based cancer vaccine by SPIO NP
was used in the first clinical trial that involved the cell tracking by
MRI techniques, where it was possible to detect the target lymph
node only in half of the patients with melanoma (De Vries et al.,
2005).
T cells have been sorted and cultured with SPIO NPs, mostly
coated by transfection agents, as poly-L-lysine or protamine sul-
fate, to promote their capture due to the non-phagocytic nature
of these immune cells (Arbab et al., 2005; Thorek and Tsourkas,
2008; Thu et al., 2012). These intracellular labeling was also
attempted through the use cell-penetrating peptides and HIV-
TAT (Torchilin, 2008).
The in vivo labeling of immune cells by SPIO NPs is often used
to track monocytes and macrophages to characterize inflamma-
tory events, due to their phagocytic behavior (Settles et al., 2011).
The in vivo labeling can be achieved by the intravenous admin-
istration of SPIO NPs, or alternatively after their direct injection
into tumor tissue. Both options were successfully used to label
immune cells and track their migration pattern toward lymph
nodes, which allows for example the definition of tumor specific
stage (Harisinghani et al., 2003).
It is important to emphasize that the cell labeling strategy
must not alter the function and normal phenotype of immune
cells, which could limit the efficacy of cellular-based therapies.
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The SPIO NPs are known as safe systems due to their biodegrad-
ability nature and usual rapid metabolization in vivo (Yu et al.,
2012). Therefore, the SPIO-based cell labeling is mostly suit-
able for short-term studies. On the other hand, false positives
may be detected after the accumulation of the detection agent in
macrophages after the destruction of labeled cells (Ahrens et al.,
2003; Thorek and Tsourkas, 2008). This disadvantage is in fact
common to different imaging reagent-labeled techniques.
The 19F MRI is a highly sensitive technique that allows the
direct quantification of labeled immune cells, as T cells and
phagocytic cells, either in vivo or ex vivo (Srinivas et al., 2009;
Helfer et al., 2010). Unlike SPIONPs, this labelingmethod usually
does not detect false positives and, once is notmetabolized in vivo,
constitutes a suitable approach for long-term studies (Janjic and
Ahrens, 2009; Srinivas et al., 2012).
The droplet surface of these PFC colloidal systems has been
changed with charged entities to potentiate their efficient delivery
at intracellular level. Therefore, the safety of these labeling systems
is increased, which has been shown using different immune cells,
as DCs and T cells (Ahrens et al., 2005; Srinivas et al., 2009; Helfer
et al., 2010; Ahrens and Bulte, 2013).
Recent studies have shown the promising combination of 19F
labeling techniques with fluorescence or NIR probes, as well as
with nuclear magnetic resonance (NMR) (Patel et al., 2013). Even
though, the use of these colloidal system for cell tracking is con-
siderably recent and further studies are urged in order to confirm
these indications.
ANIMAL MODELS FOR THE TRANSLATION OF
IMMUNOTHERAPEUTIC APPROACHES
The successful translation of alternative immune-based
approaches for cancer therapy into the clinic is highly dependent
on the development of preclinical animal models that adequately
mimic human disease progression. Several models have been
developed and successfully used to study cancer mechanisms
of disease and the efficacy of conventional therapeutic options
(Budhu et al., 2014).
Accordingly, models currently used to evaluate therapeutic
antitumor efficacy at preclinical level are based on transgenic sys-
tems and the transplantation of in vitro grown cancer cells into
healthy animals or in humanized mouse models—human tumor
xenograft models (Ostrand-Rosenberg, 2004). The implantation
of human cell lines dictates the use of immunocompromised
mice –T-cell deficient—to allow the establishment of cancer dis-
ease. Besides being one of the most used models to study cancer
disease and the effect of cytotoxic therapies, those are definitely
not suitable to test the efficacy of immunotherapeutic strategies
as it is not possible to evaluate the effect of adaptive immune
response in tumor development (Legrand et al., 2009). However,
different approaches are currently being explored to improve
their application toward the reconstitution of the immune system
using human cells (Carpenito et al., 2009; Legrand et al., 2009;
Pedroza-Gonzalez et al., 2011). Still, the evaluation of the out-
come of different immunotherapeutic options has been possible
due to development of different mouse cancer cell lines, which
can be further modified if needed: B16 melanoma, CT26 colon
carcinoma, TRAMP (transgenic adenocarcinoma of the mouse
prostate model) prostate cancer, 4T1 breast cancer, EL4 T lym-
phoma (Greenberg et al., 1995). Even tough, there is usually a
rapid tumor growth after the subcutaneous administration of
those cells and therefore these models do not mimic the long-
lasting host-tumor interactions resultant from the spontaneous
implementation of this disease. On the other hand, the trans-
plantable tumors are very versatile for prophylactic studies as it
allows establishment of different vaccination settings, allowing
an immune response before the induction of cancer disease and
consequent immunosuppressive outcomes.
The spontaneous and multi-step tumor development, includ-
ing the cross-talk between cells within tumor microenvironment
is possible in genetic modified animals (Dougan et al., 2011).
However, these animals need to be evaluated for longer periods
of time. In addition, the presence of mutations in a perma-
nent manner, in contrast to what happens in cancer disease,
has been associated with higher variability and tolerance and
consequently, lower effectiveness of different immunotherapeutic
options (Hurwitz et al., 2000; Ercolini et al., 2005).
As a result, there is an urgent need for animal models recapitu-
lating cancer disease, and all results should be discussed having in
consideration animal model specificities and limitations. In addi-
tion, different types of animal models should be tested in order to
better characterize the obtained antitumor evidences for clinical
translation.
CONCLUSIONS AND FUTURE PERSPECTIVES
Despite the improvement observed in chemotherapy and radio-
therapy for cancer treatment, the battle against this disease seems
to have more chances to be achieved through the combination of
different therapeutic modalities. Immunotherapeutic approaches
have emerging as promising tools to address the heterogene-
ity of this disease, namely those immune cell mediated cancer
therapies. It is possible to underline the advances obtained with
the approval of anti-CTL4 monoclonal antibody by the FDA,
and great expectations have arisen from the use of different
approaches to modulate the function of immune cells within
tumor site. Among those strategies, the outcome of cancer vac-
cines can be highlighted. To monitor and guide the development
of cellular therapies and the in situmanipulation of immune cells,
the improvement of non-invasive imaging strategies to obtain
detailed information regarding the biological processes within
the complex tumor microenvironment is imperative. We fore-
see the use of non-toxic nanotechnology-based systems able to
combine the specific (i) targeting of immune cells, promoting
the controlled delivery of different molecular entities to modulate
the cell-cell interactions; and (ii) tracking through the inclu-
sion of different probes to improve safety, specificity and sen-
sitivity of cell-labeling methods and imaging approaches. These
immunotheranostics are expected to enable a rational definition
of treatment plans for a particular patient, resulting in better clin-
ical outcomes and enhanced control of the disease, which can also
promote their translation into marketed systems.
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